Drug Trial Radar · NCT07502417
A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Mar 27, 2026
Primary completion
Jul 2, 2026
Study completion Jul 2, 2026
Sponsor
- Lead sponsor
- AbbVieAbbVie (ABBV)
- Sponsor type
- Industry
- First posted
- Mar 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study is to assess the effect of repeated doses of ABBV-722 on the single dose pharmacokinetics (PK) of ethinyl estradiol and levonorgestrel.
Conditions
- Healthy Volunteer
Interventions
Ethinyl Estradiol + LevonorgestrelDrug
Oral
ABBV-722Drug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Observed Plasma Concentration (Cmax) of Ethinyl Estradiol and LevonorgestrelTime frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2
- Time to Cmax (Tmax) of Ethinyl Estradiol and LevonorgestrelTime frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2
- Terminal Phase Elimination Rate Constant (β) of Ethinyl Estradiol and LevonorgestrelTime frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2
- Terminal Phase Elimination Half-Life (t1/2) of Ethinyl Estradiol and LevonorgestrelTime frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2
- Area Under the Plasma Concentration-Time Curve From Time 0 to Time of Last Measurable Concentration (AUCt) of Ethinyl Estradiol and LevonorgestrelTime frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2
- Area Under the Plasma Concentration-Time Curve From Time 0 to Infinite Time (AUCinf) of Ethinyl Estradiol and LevonorgestrelTime frame: Up to Day 5 in Period 1 and between Days 14-21 in Period 2
- Number of Participants with Adverse Events (AEs)Time frame: Up to Approximately 82 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Acpru /Id# 281745
Grayslake, Illinois
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.